EMV Capital CEO on H1 results, Destiny Pharma opportunity and Venture Building platform

EMV Capital (AIM:EMVC) CEO Dr Ilian Iliev talked with Proactive's Stephen Gunnion about the company's evolving strategy, recent investments, and focus areas following its growth to over $100 million in assets under management. Iliev noted the company has expanded from 8 to over 70 portfolio companies since its merger with NetScientific five years ago. EMV Capital continues to target deep tech and life sciences sectors, underpinned by a capital-efficient investment model. He outlined how the business is managing liquidity through diverse revenue streams and selective secondary disposals. “The core of what we're doing is we're trying to get to a point where we're covering our ongoing costs from ongoing, cash resources,” Iliev explained. A key topic was EMV Capital’s acquisition of Destiny Pharma’s IP and clinical assets. Iliev described the deal as part of a broader strategy to address antimicrobial resistance. The company implemented a venture build program to grow the value of the asset at no cash cost, adding £0.5 million of direct value to its balance sheet. He also discussed Martlet Capital’s recent 2.5x return, which he said validated EMV’s dual-playbook strategy: active venture building and minority co-investments. Looking ahead, Iliev pointed to promising growth from portfolio companies including a US-based remote patient monitoring business and Scandinavian deep tech recycling initiatives. For more interviews and updates, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe to the channel, and enable notifications for future content. #EMVCapital #IlianIliev #DestinyPharma #VentureCapital #LifeSciences #DeepTech #InvestmentStrategy #AIMStocks #ProactiveInvestors #MartletCapital #AntimicrobialResistance #PrivateEquity #HealthcareInnovation